Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production Method
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (rAAV) vectors offer promise for gene therapy of alpha-1 antitrypsin (AAT) deficiency. A toxicology study in mice evaluated intramuscular injection of an rAAV vector expressing human AAT (rAAV-CB-hAAT) produced using a herpes simplex virus (HSV) complementation system or a plasmid transfection (TFX) method at doses of 3 × 10(11) vg (1.2 × 10(13) vg/kg) for both vectors and 2 × 10(12) vg (8 × 10(13) vg/kg) for the HSV-produced vector. The HSV-produced vector had favorable in vitro characteristics in terms of purity, efficiency of transduction, and hAAT expression. There were no significant differences in clinical findings or hematology and clinical chemistry values between test article and control groups and no gross pathology findings. Histopathological examination demonstrated minimal to mild changes in skeletal muscle at the injection site, consisting of focal chronic interstitial inflammation and muscle degeneration, regeneration, and vacuolization, in vector-injected animals. At the 3 × 10(11) vg dose, serum hAAT levels were higher with the HSV-produced vector than with the TFX-produced vector. With the higher dose of HSV-produced vector, the increase in serum hAAT levels was dose-proportional in females and greater than dose-proportional in males. Vector copy numbers in blood were highest 24 hr after dosing and declined thereafter, with no detectable copies present 90 days after dosing. Antibodies to hAAT were detected in almost all vector-treated animals, and antibodies to HSV were detected in most animals that received the highest vector dose. These results support continued development of rAAV-CB-hAAT for treatment of AAT deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 5×
“Studies from a number of groups showed that the use of the AAV1 capsid in muscle was substantially more efficient than AAV2 (Xiao et al. , 1999; Chao et al. , 2001; Gao et al. , 2002; Rabinowitz et al. , 2002; Hauck and Xiao, 2003), and work from members of our group demonstrated that human AAT…”
InfluentialBrantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327 · cited 3×
“…method, the use of muscle injection for development of a clinical approach has several advantages, such as a more favorable profile of anti-capsid effector T-cell responses (Manno et al. , 2006; Brantly et al. , 2009) and a lower level of dissemination to distant sites (Manno et al. , 2003, 2006).”
Self-citationDavidoff, A. M., Ng, C. Y. C., Zhou, J., Spence, Y., & Nathwani, A. C. (2003) · Blood · doi:10.1182/blood-2002-09-2889 · Cited by 244 · cited 2×
“, 2007), but a male sex advantage has been noted after portal vein delivery of rAAV2 and rAAV5 vectors in murine studies of both factor IX and phenylalanine hydroxylase gene transfer (Davidoff et al., 2003; Mochizuki et al., 2004).”
Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1
Hauck, B., & Xiao, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2768-2774.2003 · Cited by 124
Cited by
Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Self-citationGreene, C. M., Marciniak, S. J., Teckman, J., Ferrarotti, I., Brantly, M. L., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 324
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
Pharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
“After 2–3 days, the cells and/or the media are collected and rAAV is purified over multiple purification steps to remove cellular impurities, HSV-derived contaminants, and unpackaged AAV DNA.(26,28,29) Processes utilized to date to remove process-derived impurities from rAAV stocks will be described briefly below.”
MethodMueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70314 · Cited by 169
“recombinant HSV complementation system (37).”
Self-citationTimmers, A. M., Newmark, J. A., Turunen, H. T., Farivar, T., Liu, J., Song, C., Ye, G.-J., Pennock, S., Gaskin, C., Knop, D. R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.144 · Cited by 77
Self-citationYe, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64
“Vector Characterization Vector concentration (vector genomes [VG]/ml), purity (silver-stained sodium dodecyl sulfate– polyacrylamide gel electrophoresis [SDS–PAGE] analysis), and concentrations of endotoxin and HSV protein were measured as previously described.(25) Concentrations of BHK protein, bovine serum albumin,…”
MethodSelf-citationYe, G.-J., Budzynski, E., Sonnentag, P., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Howard, K., Knop, D. R., Neuringer, M., McGill, T., et al. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.076 · Cited by 53
“We have previously used sBHK cells grown in medium containing fetal bovine serum to produce an rAAV1-CB-hAAT vector that was evaluated in patients with alpha-1 antitrypsin (AAT) deficiency.(21,32,33) The process used for purification of that vector employed a CIM Q column followed by an AVB column.”
Self-citationDufour, V. L., Cideciyan, A. V., Ye, G.-J., Song, C., Timmers, A., Habecker, P. L., Pan, W., Weinstein, N. M., Swider, M., Durham, A. C., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.297 · Cited by 39
Self-citationGootwine, E., Ofri, R., Banin, E., Obolensky, A., Averbukh, E., Ezra-Elia, R., Ross, M., Honig, H., Rosov, A., Yamin, E., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.028 · Cited by 36
“Vector characterization Vector concentrations (vg/mL), purity (silverstained sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis), and concentrations of endotoxin and HSV protein were measured, as previously described.(22) Concentrations of BHK protein, bovine serum albumin, Benzonase, and AVB ligand we…”
Self-citationGenetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Song, C., Dufour, V. L., Cideciyan, A. V., Ye, G.-J., Swider, M., Newmark, J. A., Timmers, A. M., Robinson, P. M., Knop, D. R., Chulay, J. D., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.337 · Cited by 28
“All vectors were formulated in 1 · BSST and assayed for vector genome concentration, purity, capsid and transgene identification, endotoxin levels, infectivity, and sterility as previously described.(25) Vector genome concentration was”
MethodSelf-citation
Metadata
- Authors
- Chulay, J. D., Ye, G.-J., Thomas, D. L., Knop, D. R., Benson, J. M., Hutt, J. A., Wang, G., Humphries, M., & Flotte, T. R.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2011-02
- Volume
- 22
- Issue
- 2
- Pages
- 155-165
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2011371511
- Cited by
- 60
- References
- 6
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.